BioCentury | Feb 1, 2017
Clinical News

Emixustat: Ph IIa started

...began a blinded, U.S. Phase IIa trial to evaluate 2.5, 5 and 10 mg oral emixustat...
...month in about 30 patients. Kubota Pharmaceutical Holdings Co. Ltd. (Tokyo:4596), Tokyo, Japan Product: Emixustat (ACU-4429...
...flash of light, as measured by an electroretinogram; safety Status: Phase IIa started Milestone: NA Julian Zhu ACU-4429 emixustat Kubota...
BioCentury | Jul 11, 2016
Finance

Shedding red

...China approves antibiotic Taigexyn nemonoxacin Company Setback Acucela Inc. (Tokyo:4589) / Otsuka Pharmaceutical Co. Ltd. Emixustat...
BioCentury | Jun 20, 2016
Company News

Otsuka Pharmaceutical, Acucela deal

...Acucela to co-develop and co-commercialize Acucela’s emixustat ( ACU-4429 ) and Otsuka’s OPA-6566 . The emixustat...
...Otsuka said it terminated the deal after reviewing trial data released last month in which emixustat...
...Phase IIb/III S.E.A.T.T.L.E. trial in geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Emixustat...
BioCentury | Jun 15, 2016
Company News

Acucela slides after Otsuka ends ophthalmic deals

...deals for Acucela's emixustat (formerly ACU-4429 ) and Otsuka's OPA-6566 . Last month, Acucela said emixustat...
...Tuesday it is analyzing the geographic atrophy data, will continue a Phase II study of emixustat...
...treat proliferative diabetic retinopathy, and plans to start a trial in Stargardt's disease by YE16. Emixustat...
BioCentury | May 30, 2016
Clinical News

Emixustat: Phase IIb/III data

...GA secondary to dry age-related AMD showed that once-daily 2.5, 5 and 10 mg oral emixustat...
...placebo (1.69, 1.83 and 1.84 mm 2/year, respectively, vs. 1.69 mm 2/year). All doses of emixustat...
...Acucela Inc. (Tokyo:4589), Seattle, Wash. Otsuka Pharmaceutical Co. Ltd. , Tokyo, Japan Product: Emixustat (formerly ACU-4429...
BioCentury | May 27, 2016
Clinical News

Acucela's emixustat fails in AMD study

...Acucela Inc. (Tokyo:4589) dropped Y1,000 (17%) to Y4,790 after it said emixustat (formerly ACU-4429 ) missed...
...to determine next steps for the candidate. The company said none of the study's three emixustat...
BioCentury | May 16, 2016
Clinical News

Emixustat: Phase II started

...II trial to evaluate once-daily oral emixustat for 12 weeks in 20 patients. Doses of emixustat...
...Acucela Inc. (Tokyo:4589), Seattle, Wash. Otsuka Pharmaceutical Co. Ltd. , Tokyo, Japan Product: Emixustat (formerly ACU-4429...
BioCentury | May 2, 2016
Finance

Rational retail in Japan

...best performing biotech in Japan in 1Q16 with a 233% gain. The company's lead compound, emixustat...
BioCentury | Apr 4, 2016
Finance

2Q milestones

...Parkinson's disease psychosis (PDP) PDUFA date 5/1/16 Acucela Inc. (Tokyo:4589) / Otsuka Pharmaceutical Co. Ltd. Emixustat...
BioCentury | Jan 11, 2016
Finance

Sowing season

...Parkinson's disease (PD) Ph III data 2016 Acucela Inc. (Tokyo:4589) / Otsuka Pharmaceutical Co. Ltd. Emixustat...
Items per page:
1 - 10 of 38